Academic literature on the topic 'Liposomes Therapeutic use'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Liposomes Therapeutic use.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Liposomes Therapeutic use"
1
Goins, Beth A., and William T. Phillips. "The Use of Scintigraphic Imaging During Liposome Drug Development." Journal of Pharmacy Practice 14, no. 5 (October 2001): 397–406. http://dx.doi.org/10.1106/da2m-fyju-1xxq-ppkk.
Full textAbstract:
Liposomes, spherical lipid bilayers enclosing an aqueous space, have become an important class of drug carriers. This review describes the usefulness of scintigraphic imaging during the development of liposome-based drugs. This imaging modality is particularly helpful for tracking the distribution of liposomes in the body, monitoring the therapeutic responses following administration of liposome-based drugs, and investigating the physiological responses associated with liposome administration. Scintigraphy also can be used to monitor the therapeutic responses of patients given approved liposomal drugs. Several examples describing the potential of this imaging modality during both the preclinical formulation and clinical trial stages of liposomal drug development are included. Techniques for radiolabeling liposomes as well as methods for producing scintigraphic images are also described.
2
Cattel, Luigi, Maurizio Ceruti, and Franco Dosio. "From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy." Tumori Journal 89, no. 3 (May 2003): 237–49. http://dx.doi.org/10.1177/030089160308900302.
Full textAbstract:
Many attempts have been made to achieve good selectivity to targeted tumor cells by preparing specialized carrier agents that are therapeutically profitable for anticancer therapy. Among these, liposomes are the most studied colloidal particles thus far applied in medicine and in particular in antitumor therapy. Although they were first described in the 1960s, only at the beginning of 1990s did the first therapeutic liposomes appear on the market. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome (Nexstar, Boulder, CO, USA), used as an antifungal drug, and Myocet (Elan Pharma Int, Princeton, NJ, USA), a doxorubicin-containing liposome, used in clinical trials to treat metastatic breast cancer. The second-generation liposomes (“pure lipid approach”) were long-circulating liposomes, such as Daunoxome, a daunorubicin-containing liposome approved in the US and Europe to treat AIDS-related Kaposi's sarcoma. The third-generation liposomes were surface-modified liposomes with gangliosides or sialic acid, which can evade the immune system responsible for removing liposomes from circulation. The fourth-generation liposomes, pegylated liposomal doxorubicin, were called “stealth liposomes” because of their ability to evade interception by the immune system, in the same way as the stealth bomber was able to evade radar. Actually, the only stealth liposome on the market is Caelyx/Doxil (Schering-Plough, Madison NJ, USA), used to cure AIDS-related Kaposi's sarcoma, resistant ovarian cancer and metastatic breast cancer. Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues. These features account for the much lower toxicity shown by Caelyx in comparison to free doxorubicin, in terms of cardiotoxicity, vesicant effects, nausea, vomiting and alopecia. Pegylated liposomal doxorubicin also appeared to be less myelotoxic than doxorubicin. Typical forms of toxicity associated to it are acute infusion reaction, mucositis and palmar plantar erythrodysesthesia, which occur especially at high doses or short dosing intervals. Active and cell targeted liposomes can be obtained by attaching some antigen-directed monoclonal antibodies (Moab or Moab fragments) or small proteins and molecules (folate, epidermal growth factor, transferrin) to the distal end of polyethylene glycol in pegylated liposomal doxorubicin. The most promising therapeutic application of liposomes is as non-viral vector agents in gene therapy, characterized by the use of cationic phospholipids complexed with the negatively charged DNA plasmid. The use of liposome formulations in local-regional anticancer therapy is also discussed. Finally, pegylated liposomal doxorubicin containing radionuclides are used in clinical trials as tumor-imaging agents or in positron emission tomography.
3
Deol, P., G. K. Khuller, and K. Joshi. "Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice." Antimicrobial Agents and Chemotherapy 41, no. 6 (June 1997): 1211–14. http://dx.doi.org/10.1128/aac.41.6.1211.
Full textAbstract:
One recent promising development in the modification of drug formulations to improve chemotherapy is the use of a liposome-mediated drug delivery system. The efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes were evaluated by injecting liposomal drugs and free drugs into tuberculous mice twice a week for 6 weeks. Liposome-encapsulated drugs at and below therapeutic concentrations were more effective than free drugs against tuberculosis, as evaluated on the basis of CFUs detected, organomegaly, and histopathology. Furthermore, liposomal drugs had marginal hepatotoxicities as determined from the levels of total bilirubin and hepatic enzymes in serum. The elimination of mycobacteria from the liver and spleen was also higher with liposomal drugs than with free drugs. The encapsulation of antitubercular drugs in lung-specific stealth liposomes seems to be a promising therapeutic approach for the chemotherapy of tuberculosis.
4
Xie, Yufei, Panagiota Papadopoulou, Björn de Wit, Jan C. d’Engelbronner, Patrick van Hage, Alexander Kros, and Marcel J. M. Schaaf. "Two Types of Liposomal Formulations Improve the Therapeutic Ratio of Prednisolone Phosphate in a Zebrafish Model for Inflammation." Cells 11, no. 4 (February 15, 2022): 671. http://dx.doi.org/10.3390/cells11040671.
Full textAbstract:
Glucocorticoids (GCs) are effective anti-inflammatory drugs, but their clinical use is limited by their side effects. Using liposomes to target GCs to inflammatory sites is a promising approach to improve their therapeutic ratio. We used zebrafish embryos to visualize the biodistribution of liposomes and to determine the anti-inflammatory and adverse effects of the GC prednisolone phosphate (PLP) encapsulated in these liposomes. Our results showed that PEGylated liposomes remained in circulation for long periods of time, whereas a novel type of liposomes (which we named AmbiMACs) selectively targeted macrophages. Upon laser wounding of the tail, both types of liposomes were shown to accumulate near the wounding site. Encapsulation of PLP in the PEGylated liposomes and AmbiMACs increased its potency to inhibit the inflammatory response. However, encapsulation of PLP in either type of liposome reduced its inhibitory effect on tissue regeneration, and encapsulation in PEGylated liposomes attenuated the activation of glucocorticoid-responsive gene expression throughout the body. Thus, by exploiting the unique possibilities of the zebrafish animal model to study the biodistribution as well as the anti-inflammatory and adverse effects of liposomal formulations of PLP, we showed that PEGylated liposomes and AmbiMACs increase the therapeutic ratio of this GC drug.
5
Rahman, Mahfoozur, Sarwar Beg, Amita Verma, Imran Kazmi, Farhan Jalees Ahmed, Vikas Kumar, Firoz Anwar, and Sohail Akhter. "Liposomes as Anticancer Therapeutic Drug Carrier’s Systems: More than a Tour de Force." Current Nanomedicine 10, no. 2 (August 13, 2020): 178–85. http://dx.doi.org/10.2174/2468187309666190618171332.
Full textAbstract:
A liposome is a spherical vesicle composed of a bilayer of lipid with central aqueous cavity. Liposomes are the first nano vesicular drug delivery carriers, which are successfully translated into real-time clinical application and gained great potential in the past 30 years. The characteristics of liposomes to encapsulate both hydrophilic and hydrophobic drugs, their biocompatibility and biodegradability make it attractive nanocarriers in drug delivery area. Apart from this, great technical advancement has been made to develops second-generation liposomes named as stealth liposomes, cationic liposomes, triggered release liposomes and ligand targeted liposomes. This led to widespread use of liposomes in various areas including anticancer therapeutics, diagnostics and imaging agents. Therefore, the presents review article made an extensive discussion of various liposomes and its applications in cancer treatment.
6
Roberts, Steven A., Chaebin Lee, Shrishti Singh, and Nitin Agrawal. "Versatile Encapsulation and Synthesis of Potent Liposomes by Thermal Equilibration." Membranes 12, no. 3 (March 11, 2022): 319. http://dx.doi.org/10.3390/membranes12030319.
Full textAbstract:
The wide-scale use of liposomal delivery systems is challenged by difficulties in obtaining potent liposomal suspensions. Passive and active loading strategies have been proposed to formulate drug encapsulated liposomes but are limited by low efficiencies (passive) or high drug specificities (active). Here, we present an efficient and universal loading strategy for synthesizing therapeutic liposomes. Integrating a thermal equilibration technique with our unique liposome synthesis approach, co-loaded targeting nanovesicles can be engineered in a scalable manner with potencies 200-fold higher than typical passive encapsulation techniques. We demonstrate this capability through simultaneous co-loading of hydrophilic and hydrophobic small molecules and targeted delivery of liposomal Doxorubicin to metastatic breast cancer cell line MDA-MB-231. Molecular dynamic simulations are used to explain interactions between Doxorubicin and liposome membrane during thermal equilibration. By addressing the existing challenges, we have developed an unparalleled approach that will facilitate the formulation of novel theranostic and pharmaceutical strategies.
7
Khan, David R., Maggie N. Webb, Thomas H. Cadotte, and Madison N. Gavette. "Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer." Breast Cancer: Basic and Clinical Research 9s2 (January 2015): BCBCR.S29421. http://dx.doi.org/10.4137/bcbcr.s29421.
Full textAbstract:
The use of nanocarriers such as liposomes to deliver anticancer drugs to tumors can significantly enhance the therapeutic index of otherwise unencapsulated cytotoxic agents. This is in part because of the fact that the phospholipid bilayer can protect healthy sensitive tissue from the damaging effects of these types of drugs. Furthermore, the ease with which the phospholipid bilayer surface can be modified to allow for polyethylene glycol incorporation resulting in pegylated liposomes allow for increased circulation times in vivo, and thus an overall increase in the concentration of the drug delivered to the tumor site. This explains the clinical success of the liposomal-based drug Doxil, which has proven to be quite efficacious in the treatment of breast cancer. However, significant challenges remain involving poor drug transfer between the liposome and tumor cells with this type of nontargeted drug delivery system. Thus, future work involves the development of “smart” drugs, or targeted drug delivery intended for improved colocalization between the drug and cancerous cells. While it is not possible to entirely discuss such a rapidly growing field of study involving many different types of chemotherapeutics here, in this review, we discuss some of the recent advancements involving the development of targeted liposome-based chemotherapeutics to treat breast cancer.
8
Amin, Mohamadreza, Mercedeh Mansourian, Peter C. Burgers, Bahareh Amin, Mahmoud Reza Jaafari, and Timo L. M. ten Hagen. "Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides." Pharmaceutics 14, no. 2 (February 21, 2022): 458. http://dx.doi.org/10.3390/pharmaceutics14020458.
Full textAbstract:
Modification with polyethylene glycol (PEGylation) and the use of rigid phospholipids drastically improve the pharmacokinetics of chemotherapeutics and result in more manageable or reduced side-effects. A major drawback is retarded cellular delivery of content, which, along with tumor heterogeneity, are the two main obstacles against tumor targeting. To enhance cellular delivery and reach a bigger area of a tumor, we designed liposomes decorated with two ligands: one for targeting tumor vasculature via a cyclic-pentapeptide containing arginine-glycine-aspartic acid (RGD), which impacts tumor independent of passive accumulation inside tumors, and one for extravascular targeting of tumor cells via a cell-penetrating peptide derived from human immunodeficiency virus type 1 transactivator of transcription (TAT). Liposomes with different ligand combinations were prepared and compared with respect to performance in targeting. Intravital imaging illustrates the heterogeneous behavior of RGD-liposomes in both intravascular and extravascular distribution, whereas TAT-liposomes exhibit a predictable extravascular localization but no intravascular targeting. Dual-ligand modification results in enhanced vascular targeting and a predictable extravascular behavior that improves the therapeutic efficacy of doxorubicin-loaded liposomes but also an augmented clearance rate of liposomes. However, the dual-modified liposome could be a great candidate for targeted delivery of non-toxic payloads or contrast agents for therapeutic or diagnostic purposes. Here we show that the combination of vascular-specific and tumor cell-specific ligands in a liposomal system is beneficial in bypassing the heterogeneous expression of tumor-specific markers.
9
Patel, Akshay Kumar, Shivanand K. Mutta, and Rajkumar Prasad Yadav. "Liposomes –A Overview." Asian Journal of Pharmaceutical Research and Development 9, no. 3 (June 15, 2021): 82–88. http://dx.doi.org/10.22270/ajprd.v9i3.934.
Full textAbstract:
Liposomes are sphere-shaped vesicles made up of one or more bilayers of phospholipids. The ability of delayed vesicles to transport medications, vaccines, diagnostic specialists, and other bioactive operators has accelerated development in the liposomal drug delivery system. The liposomal delivery system's pharmacyelements and pharmacokinetics properties have been altered, resulting in a higher therapeutic index and lower overall toxicity. There are many factors to consider, including size, size distribution, surface electrical potential, lamella count, and encapsulation efficacy. The use of surface modification in the development of liposomes with various mechanisms, kinetic properties, and biodistribution was discovered to be beneficial. Drug delivery, drug targeting, controlled release, and improved solubility have all been studied extensively with liposomes.
10
Barros, Cecília de, Norberto Aranha, Patrícia Severino, Eliana B. Souto, Aleksandra Zielińska, André Lopes, Alessandra Rios, et al. "Quality by Design Approach for the Development of Liposome Carrying Ghrelin for Intranasal Administration." Pharmaceutics 13, no. 5 (May 10, 2021): 686. http://dx.doi.org/10.3390/pharmaceutics13050686.
Full textAbstract:
The therapeutic use of peptides has increasingly recognized in the development of new therapies. However, the susceptible enzymatic cleavage is a barrier that needs to overcome. Nose-to-brain delivery associated with liposomes can protect peptides against biodegradation and improve the accessibility to brain targets. The aim was to develop a liposomal formulation as ghrelin carrier. The quality by design (QbD) approach was used as a strategy for method development. The initial risk assessments were carried out using a fishbone diagram. A screening design study was performed for the critical material attributes/critical process parameters (CMAs/CPPs) on critical quality attributes (CQAs). Liposomes were obtained by hydrating phospholipid films, followed by extrusion or homogenization, and coated with chitosan. The optimized liposome formulation was produced by high-pressure homogenization coated with chitosan, and the resulted were liposomes size 72.25 ± 1.46 nm, PDI of 0.300 ± 0.027, the zeta potential of 50.3 ± 1.46 mV, and encapsulation efficiency of 53.2%. Moreover, chitosan coating improved performance in ex vivo permeation and mucoadhesion analyzes when compared to the uncoated liposome. In this context, chitosan coating is essential for the performance of the formulations in the ex vivo permeation and mucoadhesion analyzes. The intranasal administration of ghrelin liposomes coated with chitosan offers an innovative opportunity to treat cachexia.
Dissertations / Theses on the topic "Liposomes Therapeutic use"
1
Chen, Xiaoyu. "Investigation of liposomes and liposomal gel for prolonging the therapeutic effects of pharmaceutical ingredients." HKBU Institutional Repository, 2013. http://repository.hkbu.edu.hk/etd_ra/1524.
Full text
2
文詩泳. "紫杉醇脂質體製備工藝和處方的改進." HKBU Institutional Repository, 2010. http://repository.hkbu.edu.hk/etd_ra/1134.
Full text
3
Kilian, Gareth. "Development and testing of liposome encapsulated cyclic dipeptides." Thesis, Nelson Mandela Metropolitan University, 2011. http://hdl.handle.net/10948/1397.
Full textAbstract:
Cyclic dipeptides have been well characterized for their multitude of biological activities, including antimicrobial and anticancer activities. Cyclo(His-Gly) and cyclo(His-Ala) have also recently been shown to possess significant anticancer activity against a range of cell lines, despite the limitations of these two molecules with respect to their physicochemical properties. Low Log P results in poor cell permeability which can often be problematic for drugs with intracellular mechanisms of action. It can also results in poor biodistribution, and theoretical Log P values for cyclo(His-Gly) and cyclo(His-Ala) were extremely low making them ideal candidates for inclusion into a nanoparticulate drug delivery system. The aim of this study was therefore to formulate and evaluate liposome-encapsulated cyclic dipeptides that increase the tumour-suppressive actions of the cyclic dipeptides, while showing a high degree of specificity for tumour cells. While liposomes are relatively simple to prepare, inter batch variation, low encapsulation and poor stability are often problematic in their production and this has lead to very few liposomal products on the market. This study aimed at using a comprehensive statistical methodology in optimizing liposome formulations encapsulating cyclo(His-Gly) and cyclo(His-Ala). Initial screening of potential factors was conducted using a 25-1 fractional factorial design. This design made use of two levels for each of the five factors and abbreviated the design to minimize runs. Although not much information is provided by these types of designs, the design was sufficient in identifying two critical factors that would be studies further in a more robust design. The two factors selected, based on the screening study, were cholesterol and stearylamine content. These two factors were then used in designing a response surface methodology (RSM) design making use of a central composite rotatable vii design (CCRD) at five levels (-1.5, -1, 0, 1, 1.5) for each factor in order to better understand the design space. Various factors influenced the measured responses of encapsulation efficiency, zeta potential, polydispersity index, cellular uptake and leakage, but most notable were the adverse effects of increasing stearylamine levels on encapsulations efficiency and cholesterol levels on leakage for both cyclo(His-Gly) and cyclo(His-Ala) liposomes. Optimized formulations were derived from the data and prepared. Fair correlation between the predicted and measured responses was obtained. The cytotoxic activity of the encapsulated cyclic dipeptides were assessed against HeLa and MCF-7 cells and found to have limited improvement in activity. However, modification of the polyethylene glycol (PEG) grafted to the liposome surface in order to target folate receptors showed good benefit in significantly decreasing the IC50 values recorded in all cells lines tested, particularly low folate HeLa cells with the lowest IC50 being recorded as 0.0962 mM for folate targeted cyclo(His-Ala). The results therefore indicate that hydrophilic cyclic dipeptides are ideal candidates for inclusion into targeted drug delivery systems such as liposomes. Key words: Liposomes, cyclo(His-Gly), cyclo(His-Ala), cyclic dipeptides, HeLa, MCF-7, folate receptors, factorial design, response surface methodology (RSM), central composite rotatable design (CCRD).
4
Dang, Lei. "A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of MicroRans in osteoclasts." HKBU Institutional Repository, 2016. https://repository.hkbu.edu.hk/etd_oa/263.
Full textAbstract:
Dysregulated microRNAs in osteoclasts could cause many skeletal diseases. The therapeutic manipulation of these pathogenic microRNAs necessitates novel, efficient delivery systems to facilitate microRNAs modulators targeting osteoclasts with minimal off-target effects. Bone resorption surfaces characterized by highly crystallized hydroxyapatite are dominantly occupied by osteoclasts. Considering that the eight repeating sequences of aspartate (D-Asp8) could preferably bind to highly crystallized hydroxyapatite, we developed a targeting system by conjugating D-Asp8 peptide with liposome for delivering microRNA modulators specifically to bone resorption surfaces and subsequently encapsulated antagomir-148a (a microRNA modulator suppressing the osteoclastogenic miR-148a), i.e. (D-Asp8)-liposome-antagomir-148a. Our results demonstrated that D-Asp8 could facilitate the enrichment of antagomir-148a and the subsequent down-regulation of miR-148a in osteoclasts in vivo, resulting in reduced bone resorption and attenuated deterioration of trabecular architecture in osteoporotic mice. Mechanistically, the osteoclast-targeting delivery depended on the interaction between bone resorption surfaces and D-Asp8. No detectable liver and kidney toxicity was found in mice after single/multiple dose(s) treatment of (D-Asp8)-liposome-antagomir-148a. These results indicated that (D-Asp8)-liposome as a promising osteoclast-targeting delivery system could facilitate clinical translation of microRNA modulators in treating those osteoclast-dysfunction-induced skeletal diseases.
5
Zhang, Xue. "Development of a targeted liposomal delivery system for encapsulated cantharidin to treat hepatocellular carcinoma." HKBU Institutional Repository, 2017. https://repository.hkbu.edu.hk/etd_oa/429.
Full textAbstract:
Background: Despite increasing incidence and morbidity globally, hepatocellular carcinoma (HCC) remains a big challenge clinically. The difficulty to treat HCC is largely due to non-specific chemotherapy causing life-threatening toxicity and severe drug-related adverse effects. Extensive studies on targeted drug delivery systems (DDS) have revealed a great potential in specific delivery of chemotherapeutics for cancer treatment, which should be a way to overcome the limitations of conventional chemotherapy. Cantharidin (CTD) is a natural product from Chinese medicine showing a great potency but narrow therapeutic window with high toxicity. Its therapeutic potential is proposed to be improved with nanoliposomal encapsulation. To explore the potential of this liposomal delivery system for HCC treatment, in this study we developed and characterized liposomal carriers with CTD encapsulated and liposomal surface modified for targeted delivery to the HCC models in vitro and in vivo. Methods: In the present study, liposomal delivery system was developed with cantharidin (CTD) encapsulated as anticancer assembly for HCC treatment. Firstly, in order to demonstrate the feasibility of liposomal encapsulation for CTD, the plain liposomal CTD was prepared and the anticancer effects were evaluated in vitro and in vivo with comparison to the free CTD formulation (Chapter 2). Then, to achieve specific penetrability of the liposomal CTD for HCC, it was further modified with a cancer cell specific penetrating peptide BR2, and its superior penetrability was evaluated on both in vitro monolayer and 3D HepG2 cells including MTT assay, cellular uptake, internalization, tumor spheroid penetration and inhibition, and in vivo subcutaneous HCC mice model (Chapter 3). Finally, the dual-functionalized liposomes with BR2 and anti-carbonic anhydrase IX (CA IX) antibody were achieved for more efficient delivery with specific penetrating and targeting properties on orthotopic HCC model (Chapter 4). Results: The key results of the study are: (1) liposomal CTD can augment the anti-proliferative effects of CTD, and enhance the anticancer efficacy on subcutaneous HepG2-bearing nude mice, which might be due to the enhanced solubility of the drug as well as intracellular delivery (Chapter 2); (2) with BR2 penetrating peptide modification, the liposomal CTD can get into cancerous cells specifically and penetrate deeper in 3D tumor models. A better tumor growth inhibition was also seen in the subcutaneous HCC mice of BR2-modified liposomes treatment than that of the other group, which could be contributed to the passive targeting of liposomes as well as the specific penetrating properties induced by BR2 peptide (Chapter 3); (3) the dual-functionalized liposomes with BR2 peptide and anti-CA IX antibody modification can enhance the drug internalization into HepG2 cells and further improve the anticancer efficacy of drugs compared to other formulations on orthotopic HCC nude mice (Chapter 4). Conclusion: These results demonstrate 1) the liposomal delivery system as a powerful tool to improve anticancer effects of chemotherapeutic agent; 2) the usefulness of BR2 and CA IX modified-liposomal nano-delivery of CTD and their combination might be a potential modality for HCC treatment. The study paved a way for clinical translational medicine of this ligands-modified liposomal delivery system for targeted treatment of HCC.
6
Tshanga, Siphokazi Sisanda. "Antibacterial activity of liposome encapsulated cyclo(TYR-PRO)." Thesis, Nelson Mandela Metropolitan University, 2011. http://hdl.handle.net/10948/1450.
Full textAbstract:
Cyclic dipeptides (CDPs) are amino acid-based compounds, some of which possess antibacterial activity. The encapsulation of certain drugs into liposomes has been found to improve their activity in terms of bioavailability and duration of action. Liposomes are small vesicles that are under investigation as drug carriers for the delivery of therapeutic agents. A number of liposome formulations are currently under clinical trial review, whilst some have already been approved for clinical use. The aim of this study was to optimize a liposomal cyclo(Tyr-Pro) formulation and to assess its antibacterial activity against various Gram-positive and Gram-negative bacteria. Response surface methodology (RSM) using the central composite design (CCD) model was used to optimize liposomal formulations of cyclo(Tyr-Pro) for each of the four bacteria, namely Bacillus cereus, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Percent drug encapsulated and bacterial inhibition were investigated with respect to two independent variables, i.e. lipid composition and cholesterol content. Design Expert 8 was used for the purpose of finding the combination of independent variables that would yield an optimal formulation for each bacterium. The model selected by the software failed to adequately correlate the predicted models to the experimental data. The in vitro experiments showed that the antibacterial activity of liposome-encapsulated cyclo(Tyr-Pro) was superior to that of its free counterpart. Binding maximum or Bmax for the encapsulated compound at concentrations as low as 0.412 mg/ml, was significantly higher than that obtained for free cyclo(Tyr-Pro) which was tested at a concentration of 20 mg/ml. Furthermore, encapsulation of cyclo(Tyr-Pro) into a liposome formulation enhanced its potency. This was evident in the lower IC50 values for the liposomal compound when compared to free cyclo(Tyr-Pro).
7
Jacoberger--Foissac, Célia. "Développement de constructions liposomiques personnalisables pour une thérapie ciblée du cancer : la vaccination antitumorale." Thesis, Strasbourg, 2018. http://www.theses.fr/2018STRAJ065.
Full textAbstract:
Un des enjeux majeurs de la thérapie contre le cancer est le développement d’immunothérapies innovantes ciblées et efficaces sur le long terme. Dans ce but, nous avons tiré profit de la versatilité des liposomes pour concevoir une plateforme vaccinale modulable associant i) un épitope peptidique CD4 universel capable de stimuler les lymphocytes T CD4+, ii) un épitope peptidique CD8 dérivé de la tumeur, induisant la différenciation des lymphocytes T CD8+ en lymphocytes T cytotoxiques et iii) un ou des agonistes des récepteurs Toll-like ou NOD-like qui agissent comme des adjuvants en activant les cellules dendritiques. Après plusieurs étapes de criblage, trois vaccins ont été développés, spécifiques d’un modèle orthotopique de cancer du poumon (TC-1) et différant uniquement par leur adjuvant. Une étude comparative dans un modèle murin a été réalisée. Ces travaux ont permis de comparer leur limite temporelle d’efficacité, de mettre en évidence leur mécanismes immunitaires respectifs et de démontrer la supériorité thérapeutique des liposomes contenant un agoniste du TLR4 (MPLA). Ces travaux ont montré l’intérêt d’une plateforme liposomique modulable pour la conception de vaccins personnalisésCurrently, a challenging goal in the area of cancer treatment is the development of innovative targeted antitumoral immunotherapies with a long-term efficiency. In this context, we took advantage of liposomal nanoparticles properties for the conception of a tunable vaccine platform allowing the strategical conception of vaccines containing: i) a CD4 epitope peptide able to stimulate CD4+ T helper cells ii) a tumor CD8 epitope peptide, which induces the differentiation of CD8+ T cells in cytotoxic T cells and iii) Toll or Nod-Like receptor agonist(s), which act as adjuvant for the activation of dendritic cell. After several screening steps, three vaccines, specific tardeting an orthotopic lung tumor model (TC-1) and differing only by their adjuvant composition, were successfully developed. Subsequently, a comparative study of their efficacy time limit and their immunologic mode of action was performed. This study showed the therapeutic supremacy of liposomal vaccines containing a TLR4 agonist (MPLA). In this work, we demonstrated the value of a customizable liposomal platform for the conception of personalized vaccines and we highlighted the necessity of immune monitoring for a better understanding of vaccines impact and the prediction of their efficacy
Books on the topic "Liposomes Therapeutic use"
1
Liposomes: From physics to applications. Amsterdam: Elsevier, 1993.
Find full text
2
Gregory, Gregoriadis, Florence A. T, and Patel Harish M. 1939-, eds. Liposomes in drug delivery. Chur, Switzerland: Harwood Academic Publishers, 1993.
Find full text
3
Otto, Braun-Falco, Korting Hans Christian, and Maibach Howard I, eds. Liposome dermatics. Berlin: Springer-Verlag, 1992.
Find full text
4
1960-, Tyle Praveen, and Ram Bhanu P. 1951-, eds. Targeted therapeutic systems. New York: Dekker, 1990.
Find full text
5
D, Lasic D., and Papahadjopoulos Demetrios, eds. Medical applications of liposomes. Amsterdam: Elsevier, 1998.
Find full text
6
1959-, Rolland Alain, ed. Pharmaceutical particulate carriers: Therapeutic applications carriers. New York: Marcel Dekker, 1993.
Find full text
7
Sugarman, Steven. Applications for liposomes in human malignancy: Current status and future directions. Austin: R.G. Landes, 1995.
Find full text
8
Price, Carl I. Local liposome drug delivery: An overlooked application. Austin, Texas: R.G. Landes Company, 1992.
Find full text
9
Price, Carl I. Local liposome drug delivery: An overlooked application. Austin: R.G. Landes, 1992.
Find full text
10
Price, Carl I. Local liposome drug delivery: An overlooked application. Austin, TX: R. G. Landes Co., 1992.
Find full textBook chapters on the topic "Liposomes Therapeutic use"
1
Rombi, G., F. Cossu, G. Melis, V. Anedda, and A. Facchini. "Therapeutic use of polyspecific mab-labelled liposomes as carriers for radioisotopes and drugs." In Cancer Treatment An Update, 826–32. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_176.
Full text
2
Sharma, Bunty, Sampan Attri, Jyoti Syal, and Ujjawal Sharma. "Liposomal Nanoparticles: A Viable Nanoscale Drug Carriers for the Treatment of Cancer." In Liposomes - Recent Advances, New Perspectives and Applications [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.109581.
Full textAbstract:
Cancer immunotherapy is emerging as a promising therapeutic modality for achieving highly efficient therapeutic performance while avoiding tumor metastasis and relapse which are most common outcome of traditional cancer therapies (surgery, chemo and radiotherapy). Liposomal nanoparticles may be an ideal platform for systemic immune modulator delivery. Liposomes, the lipid bilayer vesicles, are biocompatible biodegradable carriers that are extensively used for the delivery of both hydrophilic and hydrophobic bio actives. The advance features like structural fabrication of liposome for ligand anchoring, long-circulation, and stimuli-responsiveness are helpful for the demand of clinical and industrial uses. Recent studies have reported the manifestations of liposomal newer developments in cancer treatment. Presentchapter discusses the most recent advances in liposomal nanoparticles for cancer therapy along with ligand targeted, stimulus targeted and autophagy modulation by liposomal nanoparticles for cancer treatment.
3
Nagarsenker, Mangal Shailesh, and Megha Sunil Marwah. "Liposomes." In Advances in Medical Technologies and Clinical Practice, 52–87. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-0751-2.ch003.
Full textAbstract:
The science of liposomes has expanded in ambit from bench to clinic through industrial production in thirty years since the naissance of the concept. This chapter makes an attempt to bring to light the impregnable contributions of great researchers in the field of liposomology that has witnessed clinical success in the recent times. The journey which began in 1965 with the observations of Bangham and further advances made en route (targeting/stealthing of liposomes) along with alternative and potential liposome forming amphiphiles has been highlighted in this chapter. The authors have also summarised the conventional and novel industrially feasible methods used to formulate liposomes in addition to characterisation techniques which have been used to set up quality control standards for large scale production. Besides, the authors have provided with an overview of primary therapeutic and diagnostic applications and a brief insight into the in vivo behaviour of liposomes.
4
Jesús Villarreal-Gómez, Luis, and Graciela Lizeth Pérez-González. "Novel Drug Carries: Properties and Applications." In Drug Carriers [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.106868.
Full textAbstract:
Conventional drug administration has several issues and challenges such as full doses absorption and efficient targeting, some generate undesirable secondary effects and promote damage to organs and tissues such as the liver and kidneys, and others trigger inflammation and immune responses. Hence, drug carriers help to promote drug absorption, enhance targeting, avoid or decrease secondary effects, possess the ability to camouflage drugs from immune cells and proteins, and permit controlled release to provide prolonged drug delivery to maintain its blood concentration within therapeutic limits. Drug carriers have gained importance thanks to their various properties such as biocompatibility, biodegradability, mechanical properties, and high surface area, among others. Drug carriers are getting crucial to avoid or diminish secondary effects and improve the targeting of the administered drugs incrementing their effectiveness. Hence, this book chapter aims to introduce some drug carriers (electrospun nanofibers, aptamers, micelles, and liposomes), describing the properties and polymers used. It is observed that fast dissolving administration is the most recommended strategy for the use of drug carriers, where more evident therapeutics benefits can be appreciated.
5
Jahan, Israt. "Nanotechnology for Drug Delivery and Cancer Therapy." In Handbook of Research on Green Synthesis and Applications of Nanomaterials, 338–62. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-7998-8936-6.ch015.
Full textAbstract:
Nanotechnology facilitates exclusive opportunities for investigating and controlling a wide range of biomedical approaches at nano-scale, which could provide a groundbreaking impact on medicine, biology, and other health-related areas. This latest technology offers certain distinctive benefits in different aspects such as nanocarriers of targeted drug delivery system, diagnosis and treatment of cancer, vaccination and immunotherapy, biosensing and imaging for clinical diagnosis. A wide range of nanomaterials with biomedical prominence have already been exploited for drug delivery and cancer therapy comprising, solid lipid nanoparticles, metallic nanoparticles, polymeric nanoparticles, carbon nanotube, nanogel-based compounds, nanocapsules, magnetic nanoparticles, nanofluids, nanowires, liposomes, etc. Therefore, this chapter reviewed the potential use of different nanomaterials for therapeutic applications, especially for drug delivery and cancer diagnosis and therapy by focusing their suitability and biocompatibility for extensive and safer usages.
6
Karthikeyan, Kesavan, Nivedita Gautam, Olivia Parra-Marín, and Selvasankar Murugesan. "Gene Therapy: A New Avenue for the Management of Ophthalmic Diseases." In Nanoparticles and Nanocarriers-Based Pharmaceutical Formulations, 395–435. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815049787122010016.
Full textAbstract:
Gene therapy aims at intercellular delivery of functional genetic material to the affected area to restore its function or block a dysfunctional gene using viral vectors (Adeno-associated virus) or non-viral vectors (liposomes, SLNs). Gene therapy for the management of ocular diseases is emerging with improved and encouraging results. The Eye has well-defined anatomy, tight ocular barriers, and immune-privileged. It is a perfect target for gene therapy. Recently, many clinical trials are underway or have been completed. The success of these clinical trials promotes the treatment of several ocular diseases (Age-related macular degeneration, glaucoma, retinitis pigmentosa, and choroideremia). Gene therapy should possess an efficient targeting capacity and longstanding gene expression. Viral vectors are mainly used for gene therapy, but due to the risk associated with immunogenicity and mutagenesis, non-viral vectors are widely utilized. This chapter summarizes the recent development of therapeutic gene delivery approaches for the effective management of ocular diseases and their use in ophthalmology.
7
Lankalapalli, Srinivas, and V. S. Vinai Kumar Tenneti. "Drug Delivery through Liposomes." In Smart Drug Delivery. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.97727.
Full textAbstract:
Several efforts have been focused on targeted drug delivery systems for delivering a drug to a particular region of the body for better control of systemic as well as local action. Liposomes have proven their efficiency as a choice of carrier for targeting the drugs to the site of action. The main reason for continuous research on liposomes drug delivery is they largely attributed to the fact that they can mimic biological cells. This also means that liposomes are highly biocompatible, making them an ideal candidate for a drug delivery system. The uses found for liposomes have been wide-spread and even include drug delivery systems for cosmetics. Several reports have shown the applicability of liposomal drug delivery systems for their safe and effective administration of different classes of drugs like anti tubercular, anti cancer, antifungal, antiviral, antimicrobial, antisense, lung therapeutics, skin care, vaccines and gene therapy. Liposomes are proven to be effective in active or passive targeting. Modification of the bilayer further found to increase the circulation time, improve elasticity, Trigger sensitive release such as pH, ultrasound, heat or light with appropriate lipid compositions. The present chapter focuses on the fundamental aspects of liposomes, their structural components, preparation, characterization and applications.
8
Waghulde, Sandeep Onkar, Nilofar A. Khan, and Nilesh Gorde. "Effect of NDDS on Polyherbal Formulation." In Advances in Medical Diagnosis, Treatment, and Care, 106–48. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-4453-2.ch005.
Full textAbstract:
In India, in ancient times, people used plant materials to make drug polyherbal formulations. Herbal drugs have enormous therapeutic potential which can be explored through various beneficial drug delivery systems and novel drug delivery systems. Great advancement has been made in the uses of plant therapeutics on the development of novel herbal formulations like polymeric nanoparticles, nanocapsules, liposomes, phytosomes, nanoemulsions, microsphere, transferosomes, and ethosomes. These formulations have reported having various advantages over the traditional formulations such as improved solubility and bioavailability, reduced toxicity, controlled drug delivery, protections of plant actives from degradation. Also, having the drug targeting properties with improved selectivity, drug delivery, and effectiveness with dose reduction not only increases the safety but also patient compliance.
9
Jain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey, and Suresh P. Vyas. "Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario." In Research Anthology on Synthesis, Characterization, and Applications of Nanomaterials, 115–37. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-8591-7.ch006.
Full textAbstract:
Nanotechnology has drawn the attention of many researchers for the delivery of therapeutics used in various medical applications. Liposomes and polymeric nanoparticles represent promising nanocarriers that efficiently encapsulate drugs, which prevents their degradation along with the control and sustained drug release. Despite the many advantages of these formulations, some of the drawbacks associated with them limit their application to a certain extent. Therefore, there is need for a novel nanocarrier that possesses all of their individual advantages and excludes their drawbacks. Currently, researchers are focused on developing a novel platform that is a hybrid of a polymeric and liposomal-based carrier that combines the peculiarity of both and excludes their shortcomings. Lipid hybrid polymer nanoparticles (LPNs) contain the hydrophobic biodegradable polymeric core surrounded by a lipid layer for intensification of biocompatibility. This chapter includes an introduction of LPNs along with their advantages, composition, and method of preparation.
10
Jain, Anamika, Laxmikant Gautam, Nikhar Vishwakarma, Rajeev Sharma, Nishi Mody, Surbhi Dubey, and Suresh P. Vyas. "Emergence of Polymer-Lipid Hybrid Systems in Healthcare Scenario." In Multifunctional Nanocarriers for Contemporary Healthcare Applications, 448–70. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-4781-5.ch017.
Full textAbstract:
Nanotechnology has drawn the attention of many researchers for the delivery of therapeutics used in various medical applications. Liposomes and polymeric nanoparticles represent promising nanocarriers that efficiently encapsulate drugs, which prevents their degradation along with the control and sustained drug release. Despite the many advantages of these formulations, some of the drawbacks associated with them limit their application to a certain extent. Therefore, there is need for a novel nanocarrier that possesses all of their individual advantages and excludes their drawbacks. Currently, researchers are focused on developing a novel platform that is a hybrid of a polymeric and liposomal-based carrier that combines the peculiarity of both and excludes their shortcomings. Lipid hybrid polymer nanoparticles (LPNs) contain the hydrophobic biodegradable polymeric core surrounded by a lipid layer for intensification of biocompatibility. This chapter includes an introduction of LPNs along with their advantages, composition, and method of preparation.
Conference papers on the topic "Liposomes Therapeutic use"
1
Sarker, Sunandita, Yiannis S. Chatzizisis, Srivatsan Kidambi, and Benjamin S. Terry. "Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis." In 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6869.
Full textAbstract:
Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations have confirmed that atherosclerosis is an inflammatory disease [3] [4] [5]. This confirmation has opened the treatment of this disease to many novel anti-inflammatory therapeutics. The use of nanoparticle-nanomedicines has gained popularity over recent years. Initially approved as anticancer treatment therapeutics [6], nanomedicine also holds promise for anti-inflammatory treatment, personalized medicine, target-specific treatment, and imaging of atherosclerotic disease [7]. The primary aim of this collaborative work is to develop and validate a novel strategy for catheter-directed local treatment of high-risk plaque using anti-inflammatory nanoparticles. Preselected drugs with the highest anti-inflammatory efficacy will be incorporated into a novel liposome nanocarrier, and delivered in-vivo through a specially designed catheter to high-risk atherosclerotic plaques. The catheter has specially designed perfusion pores that inject drug into the blood stream in such a controlled manner that the streamlines carry the nanoparticles to the stenotic arterial wall. Once the particles make it to the arterial wall, they can be absorbed into the inflamed tissue. In this paper, we discuss the design and development of an atraumatic drug delivery catheter for the administration of lipid nanoparticles.